Buy Ambuja Cements Ltd. at a price target of Rs 220.0 and a stoploss at Rs 210 from entry point.|Updated: Aug 19, 2019, 09.04 AM ISTIndependent analyst Kunal Bothra has a buy call on Ambuja Cements Ltd. with a target price of Rs 220. The current market price of Ambuja Cements Ltd. is Rs 213.95. Time period given by the analyst is Intra Day when Ambuja Cements Ltd. price can reach the defined target. Kunal Bothra recommended to keep stoploss at Rs 210. Ambuja Cements Ltd., incorporated in 1981, has a market cap of Rs 42482.88 crore.
Ambuja Cements Ltd. key Products/Revenue Segments include Cement which contributed Rs 10977.00 Crore to Sales Value (96.65 % of Total Sales), Other Operating Revenue which contributed Rs 337.66 Crore to Sales Value (2.97 % of Total Sales) and Scrap which contributed Rs 42.10 Crore to Sales Value (0.37 % of Total Sales)for the year ending 31-Dec-2018.
For the quarter ended 30-06-2019, the company has reported a Consolidated sales of Rs 7068.79 Crore, up 3.49 % from last quarter Sales of Rs 6830.70 Crore and up 3.42 % from last year same quarter Sales of Rs 6835.12 Crore Company has reported net profit after tax of Rs 827.45 Crore in latest quarter. The company’s top management includes Dr.Omkar Goswami, Mr.Bimlendra Jha, Mr.Christof Hassig, Mr.Jan Jenisch, Mr.Mahendra Kumar Sharma, Mr.Martin Kreigner, Mr.N S Sekhsaria, Mr.Nasser Munjee, Mr.Praveen Kumar Molri, Mr.Rajendra P Chitale, Mr.Ranjit Shahani, Mr.Roland Kolher, Mr.Shailesh Haribhakti, Ms.Shikha Sharma, Ms.Then Hwee Tan. Company has Deloitte Haskins & Sells LLP as its auditors. As on 30-06-2019, the company has a total of 1,985,645,229 shares outstanding.
Read this article in :HindiAlso ReadBuy Vedanta, target Rs 178: Kunal BothraBuy Vedanta, target Rs 175: Kunal BothraThere could be more pain left for the indices: Kunal BothraBuy Biocon, target Rs 272 : Kunal BothraBuy DLF, target Rs 200: Kunal BothraCommenting feature is disabled in your country/region.Disclaimer: This recommendation is analyst’s own and does not represent those of & Please consult your financial advisor before taking any position in the stock/s mentioned.Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service